Editas Medicine Inc (EDIT) has a current Price-to-Book (P/B) ratio of 14.21. Compared to its 3-year average P/B ratio of 4.22, the current P/B ratio is approximately 237.16% higher. Relative to its 5-year average P/B ratio of 3.80, the current P/B ratio is about 274.42% higher. Editas Medicine Inc (EDIT) has a Forward Free Cash Flow (FCF) yield of approximately -90.30%. Compared to its 3-year average FCF yield of -68.19%, the current FCF yield is approximately 32.42% lower. Relative to its 5-year average FCF yield of -45.74%, the current FCF yield is about 97.40% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for EDIT competitors is 5.53, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT.O) exhibits a P/S ratio of 11.01, which is 99.18% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of EDIT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of EDIT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is EDIT currently overvalued or undervalued?

What is Editas Medicine Inc (EDIT) fair value?

EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Editas Medicine Inc (EDIT) is between 1.70 to 2.63 according to relative valuation method.

How does EDIT's valuation metrics compare to the industry average?

The average P/S ratio for EDIT's competitors is 5.53, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of 11.01, which is 99.18% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.

What is the current P/B ratio for Editas Medicine Inc (EDIT) as of Mar 03 2026?

As of Mar 03 2026, Editas Medicine Inc (EDIT) has a P/B ratio of 14.21. This indicates that the market values EDIT at 14.21 times its book value.

What is the current FCF Yield for Editas Medicine Inc (EDIT) as of Mar 03 2026?

As of Mar 03 2026, Editas Medicine Inc (EDIT) has a FCF Yield of -90.30%. This means that for every dollar of Editas Medicine Inc's market capitalization, the company generates -90.30 cents in free cash flow.

What is the current Forward P/E ratio for Editas Medicine Inc (EDIT) as of Mar 03 2026?

As of Mar 03 2026, Editas Medicine Inc (EDIT) has a Forward P/E ratio of -1.78. This means the market is willing to pay $-1.78 for every dollar of Editas Medicine Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Editas Medicine Inc (EDIT) as of Mar 03 2026?

As of Mar 03 2026, Editas Medicine Inc (EDIT) has a Forward P/S ratio of 11.01. This means the market is valuing EDIT at $11.01 for every dollar of expected revenue over the next 12 months.

EDIT Valuation